{"brief_title": "A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)", "brief_summary": "The purpose of this study is to evaluate the relative efficacy and safety of prophylactic heparin co-administration during drotrecogin alfa (activated) infusion in the treatment of severe sepsis in the adult.", "condition": "Sepsis", "intervention_type": "Drug", "intervention_name": "Low molecular weight heparin", "criteria": "Inclusion Criteria - Adults greater than or equal to 18 years of age - Receiving inpatient treatment for severe sepsis - Indicated for treatment with Drotrecogin Alfa (Activated) under approved label in the country where the patient is enrolled Exclusion Criteria - Contraindicated for heparin treatment - Require a higher dose of heparin than defined in the trial - Have acute or chronic renal failure with an estimated creatinine clearance less than 30mL/min - Weigh more than 135 kg (297 pounds) - Are not expected to survive 28 days given their medical condition.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00049777.xml"}